Abionic, a Lausanne, Switzerland-based medical device startup, closed a CHF3.8m Series B financing round.
The round was led by MedHoldings SA with participation from BlueOcean Ventures, NE Holding, Drexel Morgan & Co. and other business angels. In addition to the funding, serial entrepreneur Martine Reindle and Urs Amstutz, Founder and former CEO of Stallergènes Switzerland, joined Abionic’s Board of Directors.
The company intends to use the funds to obtail FDA 510k certification and start commercialization of its product in 2015.
Founded in 2010 as a spinoff from EPFL (Swiss Federal Institute of Technology Lausanne, Switzerland), Abionic uses advanced technologies to provide abioSCOPE, a diagnostic tool designed to give patients personal allergy profiles.
It provides allergy diagnoses by mixing the patient’s blood sample with a proprietary reagent and placing it into a special test capsule that contains multiple biosensors capable of detecting a specific range of allergies.
abioSCOPE tests are designed to be complementary to skin tests and to offer specific, quantitative and personalized serological in vitro allergy analysis at the point-of-care.